Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (542)	8/15/2001 10:26:40 PM
From: Biomaven	Read Replies (3) \| Respond to of 656

Thanks, IJ. Significantly, Remicade is getting a Black Box warning (proposed by J&J) on TB: Black Box Warning/RISK OF INFECTIONS TUBERCULOSIS, FREQUENTLY DISSEMINATED OR EXTRAPULMONARY AT CLINICAL PRESENTATION, AND OTHER OPPORTUNISTIC INFECTIONS, INCLUDING LISTERIOSIS, HISTOPLASMOSIS AND OTHER INVASIVE FUNGAL INFECTIONS HAVE BEEN OBSERVED IN PATIENTS RECEIVING REMICADE. SOME OF THESE INFECTIONS HAVE BEEN FATAL (SEE WARNINGS). PATIENTS SHOULD BE SCREENED FOR TUBERCULOSIS WITH A PPD SKIN TEST. PATIENTS SHOULD BE TREATED FOR LATENT TUBERCULOSIS INFECTION PRIOR TO THERAPY WITH REMICADE. Enbrel doesn't seem to be getting a matching warning. Note the AMGN arthritis drug is up for discussion - I don't believe it will really compete against Enbrel/Remicade, as it seems quite a lot less effective. Peter